Tissue Regenix Group PLC - Hardman & Co Insight: Survival of the UK life sciences sector
For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This...
Hardman & Co Research: Tissue Regenix (TRX) - Six consecutive periods of >20% growth
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone...
No more insights